Antisense Oligonucleotides: Pharmacology and Delivery Strategies
Author(s) -
Mohammed Abdul Samad,
Kavya Pandiri,
Anjani Prasad Bojanapally
Publication year - 2020
Publication title -
international journal of applied pharmaceutical sciences and research
Language(s) - English
Resource type - Journals
ISSN - 2455-8095
DOI - 10.21477/ijapsr.5.1.2
Subject(s) - nanocarriers , oligonucleotide , antisense therapy , drug delivery , pharmacology , computational biology , medicine , drug , nanotechnology , chemistry , biology , materials science , biochemistry , gene , locked nucleic acid
Antisense oligonucleotide therapy is a dominant drug discovery approach that can explicitly modify protein synthesis through numerous mechanisms. The limitations of antisense oligonucleotide (ASO) therapy in delivery strategies have been overcome in recent years with different ligands carriers, as well as, through nanocarriers. ASO therapy was successfully applied towards targeting a wide range of therapeutic areas. There is an expanding enthusiasm in extending the utilization of antisense compounds to numerous different diseases due to their safe and potential therapeutic outcomes. Thus, the present review attempted to elaborate on the fundamental idea of antisense technology, approaches, and safe and effective delivery methods.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom